Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response matches several label elements (indications, IL-17A mechanism, general subcutaneous use, and some safety concepts) but contains material dosing/administration inaccuracies (notably psoriatic arthritis pediatric age/weight dosing thresholds and missing label-specific monitoring/testing instructions).
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Label indications include plaque psoriasis (1.1), psoriatic arthritis (1.2), and ankylosing spondylitis (1.3).
Cosentyx works by blocking the action of interleukin-17A (IL-17A).
Mechanism of action: selectively binds IL-17A and inhibits its interaction with the IL-17 receptor (12.1).
Cosentyx is administered by injection.
Dosage forms include injections for subcutaneous and intravenous use (3).
Cosentyx can be given subcutaneously (under the skin) or intravenously (into a vein).
Label includes subcutaneous and intravenous regimens; subcutaneous devices are for subcutaneous use only and vials are for intravenous use in adult patients only (2.2, 3; also mentions IV regimens in dosing sections).
For adults with moderate to severe plaque psoriasis, the recommended dosage of Cosentyx is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
Recommended subcutaneous dosage in adults: 300 mg at Weeks 0-4 and every 4 weeks thereafter (2.3).
For children and adolescents with moderate to severe psoriasis who weigh 40 kg or more, the recommended dosage of Cosentyx is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
Pediatric plaque psoriasis is weight-based with >=50 kg receiving 150 mg in the provided excerpt (2.3). Note: the claim states a 40 kg threshold and 300 mg, which is not supported by the excerpt; therefore this exact statement is not supported. (See unsupportedStatements.)
For children weighing less than 40 kg, a lower dose is used (150 mg vs 300 mg).
Label excerpt indicates pediatric plaque psoriasis is weight-based and includes a lower pediatric dose option depending on weight (2.3). (However the specific threshold and dose amounts in the claim do not match the excerpt; see unsupported/contradiction findings.)
Cosentyx may cause injection site reactions.
Label excerpt provided does not explicitly mention injection site reactions as an adverse reaction. (See unsupportedStatements.)
In rare cases, Cosentyx may cause anaphylaxis.
Warnings/precautions: serious hypersensitivity reactions including anaphylaxis have been reported (5.2). (Label excerpt does not use the term 'rare cases'; nevertheless anaphylaxis is explicitly included.)
In rare cases, Cosentyx may cause Stevens-Johnson syndrome.
No supplied label excerpt mentions Stevens-Johnson syndrome specifically. (See unsupportedStatements.)
In rare cases, Cosentyx may cause lupus-like reactions.
No supplied label excerpt mentions lupus-like reactions specifically. (See unsupportedStatements.)
Unsupported Statements
For children and adolescents with moderate to severe psoriasis who weigh 40 kg or more, the recommended dosage of Cosentyx is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
Provided label excerpt for pediatric plaque psoriasis uses a different weight threshold and different doses: <50 kg: 75 mg; >=50 kg: 150 mg (2.3). The claim states >=40 kg and 300 mg, which is not supported.
For children and adolescents with moderate to severe psoriasis who weigh less than 40 kg, the recommended dosage of Cosentyx is 150 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks.
Provided label excerpt specifies <50 kg: 75 mg (not 150 mg) for pediatric plaque psoriasis (2.3).
For adults with moderate to severe psoriatic arthritis, the recommended dosage of Cosentyx is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
Provided label excerpt for adult PsA includes 150 mg regimens for the loading schedule and a consideration to increase to 300 mg every 4 weeks if active disease continues (2.4). The claim asserts 300 mg as the recommended regimen, which is not supported by the excerpt.
For children and adolescents with moderate to severe psoriatic arthritis who weigh 40 kg or more, the recommended dosage of Cosentyx is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
Provided label excerpt (2.5) for pediatric PsA uses different weight thresholds/doses: >=15 kg and <50 kg: 75 mg; >=50 kg: 150 mg, and does not support 40 kg or 300 mg dosing.
For children and adolescents with moderate to severe psoriatic arthritis who weigh less than 40 kg, the recommended dosage of Cosentyx is 150 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks.
Provided label excerpt (2.5) indicates <50 kg: 75 mg (not 150 mg) for pediatric PsA.
Cosentyx is approved for use in children and adolescents as young as 6 years old.
The provided label excerpts support pediatric plaque psoriasis starting at 6 years (1.1) but do not support 'as young as 6 years old' as a blanket approval across the other indicated conditions mentioned (e.g., AS starts at 12 in the excerpt; PsA at 2 in the excerpt). This statement is partially supported only for plaque psoriasis, not generally for all claimed indications.
The dosage of Cosentyx may vary depending on the patient's age and weight.
The excerpt supports weight-based pediatric dosing (e.g., 2.3, 2.5, 2.9, 2.10) but does not explicitly state that dosing varies based on age; age-specific eligibility is described (indications and pediatric sections), yet 'dose may vary depending on age' is not directly supported as written.
Children weighing less than 40 kg may require a lower dosage of Cosentyx to minimize the risk of adverse effects.
The label excerpt provides weight-based dosing but does not provide the specific 40 kg threshold and does not link the threshold choice to 'minimize the risk of adverse effects' as written.
Cosentyx may cause injection site reactions.
The supplied label excerpts do not mention injection site reactions explicitly.
Cosentyx may cause upper respiratory tract infections.
The supplied label excerpts mention infections broadly (including opportunistic infections) but do not specifically mention upper respiratory tract infections.
Cosentyx may cause fatigue.
The supplied label excerpts do not mention fatigue.
Patients taking Cosentyx should be monitored closely for signs of adverse effects such as injection site reactions or upper respiratory tract infections.
The provided label excerpt includes monitoring considerations for TB evaluation and immunizations prior to initiation (2.1) and specific precautions such as IBD monitoring for signs/symptoms (5.4), but does not specifically include the suggested monitoring examples (injection site reactions or upper respiratory tract infections) as written.
Contradictions
Low
AI Statement
For adults with moderate to severe psoriatic arthritis, the recommended dosage of Cosentyx is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
Label Reference
Adult PsA excerpt: 150 mg loading schedule; consider increasing to 300 mg every 4 weeks if active PsA continues (2.4).
Low
AI Statement
For children and adolescents with moderate to severe psoriasis who weigh 40 kg or more, the recommended dosage of Cosentyx is 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
Label Reference
Pediatric plaque psoriasis excerpt: patients <50 kg: 75 mg; ≥50 kg: 150 mg (2.3).
Important Omissions
Pre-treatment evaluation for tuberculosis (TB) (evaluate for active/latent TB; avoid in active TB; treat latent TB before initiation).
Importance:
Moderate
Pre-treatment vaccination guidance (complete age-appropriate vaccinations before initiating; avoid live vaccines).
Importance:
Moderate
Contraindication: previous serious hypersensitivity reaction to secukinumab or excipients (and related reports).
Importance:
Moderate
Label-specific warning about inflammatory bowel disease (IBD) exacerbations and need for caution/monitoring for IBD symptoms.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several dosing details (especially pediatric thresholds and adult PsA loading dosing) are inconsistent with the provided label excerpts, which could lead to incorrect dosing. The response also omits key pre-treatment requirements (TB evaluation and vaccination/living vaccine avoidance) and does not cover IBD warning monitoring.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Multiple material mismatches with label dosing for pediatric plaque psoriasis and psoriatic arthritis, including incorrect weight thresholds and dose amounts; adult PsA loading regimen asserted as 300 mg when label excerpt indicates 150 mg with possible increase.
Suggested Improvement
Align all weight-based pediatric dosing to the label-provided thresholds/dose levels (e.g., plaque psoriasis <50 kg vs ≥50 kg; PsA pediatric per provided 2.5) and reflect adult PsA dosing as labeled (150 mg loading; consider 300 mg every 4 weeks only if active disease continues). Add label-required pre-treatment TB evaluation and immunization/live vaccine guidance, and include the contraindication and key warnings not mentioned (e.g., IBD).